Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19
Management of an Immunocompromised Pediatric Patient With Multiple Hospitalizations for Symptomatic COVID-19
复制标题
DOI：
10.1097/mph.0000000000002014
复制
发表时间：
2022-01-01
影响因子：
1.2
通讯作者：
Boguniewicz, Juri
中科院分区：
文献类型：
--
作者：
DeVine, Mackenzie N.;Maxwell, Sarah;Boguniewicz, Juri
SARS-CoV-2引起的感染复发很少被描述，并且关于免疫功能低下宿主中此类病例的管理也几乎没有指导。我们介绍了一例患有B细胞急性淋巴细胞白血病的青少年女性患者，她因症状性SARS-CoV-2感染多次住院，接受了2个疗程的瑞德西韦（RDV）安全治疗，迄今为止没有再入院。虽然需要更多的研究来证实在复发或长期严重COVID-19的情况下额外的RDV疗程的安全性和有效性，但我们的观察结果表明，可以考虑第二个RDV疗程。
Relapse of infection due to SARS-CoV-2 has been rarely described and there is little guidance regarding the management of such cases in immunocompromised hosts. We present a case of an adolescent female with B-cell acute lymphoblastic leukemia hospitalized multiple times for symptomatic SARS-CoV-2 infection who was safely treated with 2 courses of remdesivir (RDV) and has had no additional readmissions to date. Though additional studies are needed to confirm the safety and efficacy of an additional course of RDV in the setting of relapsed or prolonged severe COVID-19, our observations suggest that a second course of RDV may be considered.